← All diseases

Inborn errors of metabolism

Acute intermittent porphyria (AIP)

An inherited disorder in making heme. Most people who carry the gene have no symptoms. Some people have attacks that come with severe belly pain.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

Orphanet has a guideline for emergency doctors for this disease (language: French, Polish, English, Spanish, Italian). See on Orphanet

Prepare an emergency card

This page is translated from the Turkish original.

This disease is followed through the “Inborn errors of metabolism” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

A change in the HMBS gene reduces an enzyme that makes heme. Heme is an important part of the protein in blood that carries oxygen. Some medicines, fasting, alcohol or hormone changes can trigger an attack. Then in-between substances build up in the liver and affect the nerves.

Which symptoms can occur?

Symptoms come in attacks. Attacks usually begin in a person's 20s or 30s and are more common in women. Most people are well between attacks.

  • Severe, widespread belly pain (the most common symptom)
  • Nausea, vomiting, constipation
  • Dark or reddish urine
  • Numbness in the arms and legs, muscle weakness
  • Fast heartbeat and high blood pressure
  • Anxiety, sleeplessness, changes in consciousness
  • Seizures (fits)

How is it diagnosed?

This disease is considered in attacks of unexplained belly pain. During an attack, a substance called porphobilinogen is found to be high in the urine. Other tests tell the type apart. A genetic test helps screen family members.

Treatment and care

A severe attack is treated in hospital. Heme-containing treatment through a vein and sugar support are used. For adults who have frequent attacks, there is also an approved preventive treatment specific to the disease. Avoiding triggers is important. Before taking a new medicine, it should be checked whether it is safe. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

The disease is passed on through dominant inheritance. A parent who carries the gene has a 50 percent chance of passing it to each child. But most people who carry the gene never have an attack. Once a diagnosis is made in the family, genetic testing may be offered to relatives. Genetic counselling guides the family.

Source: MedlinePlus Genetics: Porphyria · NORD: Acute Intermittent Porphyria

Key facts

How common is it?
New cases per year: <1 per 1 000 000 (Europe) · Prevalence: 1-9 per 1 000 000 (Europe)
How is it inherited?
Autosomal dominant
When does it usually start?
Adolescence, Adulthood
Gene(s) involved
HMBS

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

We could not find a patient association specific to this disease.

For all rare diseases: Nadir Hastalıklar Federasyonu

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about Acute porphyria (AIP)

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

Questions you can ask your doctor

  • Could this trial be suitable for us?
  • If we take part, how would current treatment and check-ups be affected?
  • Where does the trial take place, and how are travel and accommodation handled?
  • What happens if we want to leave the trial?

ClinicalTrials.gov lists 1 active interventional study for this disease. 1 is recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.

Selected records (studies with a site in Türkiye first):

See all studies on ClinicalTrials.gov · Joining clinical trials

Inborn errors of metabolism: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:79276

No separate ICD-11 code; WHO classifies this disease under: 5C58.1Y

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.